Management of the behavioral complications of dementia, including agitation and aggression, presents a tremendous challenge to families and caregivers of afflicted patients. Most previous pharmacotherapies have shown minimal efficacy and significant side effects. We report our initial, open-label experience using the anticonvulsant sodium valproate in four dementia patients with severe behavioral disturbance. The drug was well tolerated by all patients, with no side effects or laboratory abnormalities, during 1- to 3-month trials. Two patients showed significant improvement in behavior, and a third had a transient response. Valproate may be a useful agent in the treatment of behavioral disturbance in dementia; controlled trials are needed to document its efficacy.
Get full access to this article
View all access options for this article.
References
1.
1. Burns A, Jacoby R, Levy R: Psychiatric phenomena in Alzheimer's disease. IV: Disorders of behaviour. Br J Psychiatry1990; 157:86–94.
2.
2. Deutsch LH, Rovner BW: Agitation and other noncognitive abnormalities in Alzheimer's disease. Psychiatr Clin North Am1991; 14:341–351.
3.
3. Reisberg B, Borenstein J, Salob SP, et al: Behavioral symptoms in Alzheimer's disease: Phenomenology and treatment. J Clin Psychiatry1987; 48(suppl):9–15.
4.
4. Wragg RE, Jeste DV: Overview of depression and psychosis in Alzheimer's disease. Am J Psychiatry1989, 146:577–587.
5.
5. Drevets WC, Rubin EH: Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type. Biol Psychiatry1989; 25:39–48.
6.
6. Rosen J, Zubenko GS: Emergence of psychosis and depression in the longitudinal evaluation of Alzheimer's disease. Biol Psychiatry1991; 29:224–232.
7.
7. Maletta GJ: Management of behavior problems in elderly patients with Alzheimer's disease and other dementias. Clin Geriatr Med1988; 4:719–747.
8.
8. Chrisman M, Tabar D, Whall AL, et al: Agitated behavior in the cognitively impaired elderly. J Gerontol Nurs1991; 17:9–13.
9.
9. Roper JM, Shapira J, Chang BL: Agitation in the demented patient. A framework for management. J Gerontol Nurs1991; 17:17–21.
10.
10. Risse SC, Barnes R: Pharmacologic treatment of agitation associated with dementia. J Am Geriatr Soc1986; 34:368–376.
12. Devanand DP, Sackeim HA, Brown RP, et al: A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer's disease. Arch Neurol1989; 46:854–857.
13.
13. Wragg RE, Jeste DV: Neuroleptics and alternative treatments. Management of behavioral symptoms and psychosis in Alzheimer's disease and related conditions. Psychiatr Clin North Am1988; 11:195–213.
14.
14. Schneider LS, Pollock VE, Lyness SA: A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc1990; 38:553–563.
15.
15. Pauszek ME: Propranolol for treatment of agitation in senile dementia. Indiana Med1991; 84:16–17.
16.
16. Weiler PG, Mungas D, Bernick C: Propranolol for the control of disruptive behavior in senile dementia. J Geriatr Psychiatry Neurol1988; 1:226–230.
17.
17. Holton A, George K: The use of lithium in severely demented patients with behavioural disturbance, letter. Br J Psychiatry1985; 146:99–100.
18.
18. Stern RG, Duffelmeyer ME, Zemishlani Z, et al: The use of benzodiazepines in the management of behavioral symptoms in demented patients. Psychiatr Clin North Am1991; 14:375–384.
19.
19. Colenda C: Buspirone in treatment of agitated demented patient. Lancet1988; 1:1169.
20.
20. Simpson DM, Foster D: Improvement in organically disturbed behavior with trazodone treatment. J Clin Psychiatry1986; 47:191–193.
21.
21. Mellow AM, Aronson SM: New pharmacologic approaches for behavioral symptoms in Alzheimer's disease, in Lawlor BA (ed): Behavioral Complications in Alzheimer's Disease. Washington, DC, American Psychiatric Press, in press.
22.
22. Schneider LS, Sobin PS: Non-neuroleptic medications in the management of agitation in Alzheimer's disease and other dementia: A systematic review. Int J Geriatr Psychiatry, in press.
23.
23. Leibovici A, Tariot PN: Carbamazepine treatment of agitation associated with dementia. J Geriatr Psychiatry Neurol1988; 1:110–112.
24.
24. Patterson JF: A preliminary study of carbamazepine in the treatment of assaultive patients with dementia. J Geriatr Psychiatry Neurol1988; 1:21–23.
25.
25. Gleason RP, Schneider LS: Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics. J Clin Psychiatry1990; 51:115–118.
26.
26. McElroy SL, Keck PE, Pope HG, Hudson JI: Valproate in psychiatric disorders: Literature review and clinical guidelines. J Clin Psychiatry1989; 50(suppl):23–29.
27.
27. Hayes SG: Long-term use of valproate in primary psychiatric disorders. J Clin Psychiatry1989; 50(suppl):35–39.
28.
28. Pope HG, McElroy SL, Keck PE, et al: Valproate in the treatment of acute mania. A placebo-controlled study. Arch Gen Psychiatry1991; 48:62–68.
29.
29. Keck PE, McElroy SL, Friedman LM: Valproate and carbamazepine in the treatment of panic and posttraumatic stress disorders, withdrawal states and behavioral dyscontrol syndromes. J Clin Psychopharmacol1992; 12:36S–41S.
30.
30. Folstein MF, Folstein SE, McHugh PR: “Mini-Mental State.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res1975; 12:189–198.
31.
31. Loscher W: Valproic acid, in Frey H-H, Janz D (eds): Antiepileptic Drugs. Handbook of Experimental Pharmacology, vol 74. Berlin, Springer-Verlag, 1985, pp. 507–537.
32.
32. Rae-Grant A, Blume W, Lau C, et al: The electroencephalogram in Alzheimer-type dementia: A sequential study correlating the electroencephalogram with psychometric and quantitative pathologic data. Arch Neurol1987; 44:50–54.
33.
33. Berrios GE, Bakshi N: Manic and depressive symptoms in the elderly: Their relationship to treatment outcome, cognition and motor symptoms. Psychopathology1991; 24:31–38.
34.
34. Loscher W, Vetter M: In vivo effects of aminooxyacetic acid and valproic acid on nerve terminal (synaptosomal) GABA levels in discrete brain areas of the rat. Correlation to pharmacological activities. Biochem Pharmacol1985; 34:1747–1756.
35.
35. Ellison DW, Beal MF, Mazurek MF, et al: A postmortem study of amino acid neurotransmitters in Alzheimer's disease. Ann Neurol1986; 20:616–621.
36.
36. Hardy J, Cowburn R, Barton A, et al: A disorder of cortical GABAergic innervation in Alzheimer's disease. Neurosci Lett1987; 73:192–196.
37.
37. Mohr E, Bruno G, Foster N, et al: GABA-agonist therapy for Alzheimer's disease. Clin Neuropharmacol1986; 9:257–263.
38.
38. Puglisi AS, Simler S, Kempf E, et al: Involvement of the GABAergic system on shock-induced aggressive behavior in two strains of mice. Pharmacol Biochem Behav1981; 1:13–18.
39.
39. Simler S, Puglisi AS, Mandel P: Effects of n-dipropylacetate on aggressive behavior and brain GABA level in isolated mice. Pharmacol Biochem Behav1983; 18:717–720.
40.
40. Kahn DE, Stevenson E, Douglas CJ: Effect of sodium valproate in three patients with organic brain syndromes. Am J Psychiatry1988; 145:1010–1011.
41.
41. Mattes JA: Valproic acid for nonaffective aggression in the mentally retarded. J Nerv Ment Dis1992; 180:601–602.
42.
42. Mazure CM, Druss BV, Cellar JS: Valproate treatment of older psychotic patients with organic mental syndromes and behavioral dyscontrol. J Am Geriatr Soc1992; 40:914–916.
